Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Horizon Therapeutics (NQ: HZNP )

99.25 -0.17 (-0.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 9, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,664,380
Open 99.30
Bid (Size) 98.78 (1)
Ask (Size) 99.76 (1)
Prev. Close 99.42
Today's Range 99.22 - 99.97
52wk Range 57.84 - 113.83
Shares Outstanding 228,621,802
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Is AbbVie or Amgen the Better Bargain Buy Right Now?
These elite drugmakers are both working through a number of headwinds. 
Via The Motley Fool
Horizon Therapeutics plc announces premium partnership with KPMG Women’s Irish Open
From Horizon Therapeutics plc
Via Business Wire

Performance

YTD
-12.56%
-12.56%
1 Month
-10.10%
-10.10%
3 Month
-9.81%
-9.81%
6 Month
+2.01%
+2.01%
1 Year
+14.01%
+14.01%

More News

Read More
Horizon Therapeutics plc Announces Data from the TEPEZZA® (teprotumumab-trbw) Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease (TED) to be Presented at the Upcoming Endocrine Society (ENDO) Annual Meeting
From Horizon Therapeutics plc
Via Business Wire
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Via Investor's Business Daily
Is Amgen a Good Dividend Stock?
Via The Motley Fool
Rule 8.1 Dealing Disclosure (Horizon Therapeutics plc)
From Horizon Therapeutics plc
Via Business Wire
3 Undervalued Biotech Stocks to Buy Before They Blast Off
Via InvestorPlace
Biomarker Analysis Publication Highlights Key Signals of Disability Worsening Associated With Neuromyelitis Optica Spectrum Disorder (NMOSD) Attacks, Illustrates Efficacy of UPLIZNA® (inebilizumab-cdon)
From Horizon Therapeutics plc
Via Business Wire
Presentations at the 2023 EULAR European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’s Syndrome
From Horizon Therapeutics plc
Via Business Wire
New Analyses of the MIRROR Randomized Controlled Trial in Uncontrolled Gout Presented at the 2023 EULAR European Congress of Rheumatology
From Horizon Therapeutics plc
Via Business Wire
3 Stocks Worth Buying at 52-Week Lows
Via MarketBeat
FTC Wants to Block the Amgen-Horizon Deal: Is Pfizer's Acquisition of Seagen at Risk, Too?
Via The Motley Fool
Horizon Therapeutics plc Announces Presentation of Data that Advances the Understanding of Rheumatic Diseases at the 2023 EULAR European Congress of Rheumatology
From Horizon Therapeutics plc
Via Business Wire
Stock Market Rally Hits 2023 Highs As Big Techs Lead; Tesla, Walmart, On Holding In Focus: Weekly Review
Via Investor's Business Daily
Is Pfizer's Seagen Deal In Jeopardy Amid Antitrust Scrutiny?
Via MarketBeat
Topics Bonds
Exposures Debt Markets
The FTC, Amgen, And Horizon: A New Hurdle For Biotech Deal Making Or Regulatory Overreach?
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
FDA Signals Support For Pfizer's Maternal RSV Shot Ahead Of Adcomm, Pfizer Raises $31B In Debt To Fund Seagen Deal
Via Benzinga
Horizon Therapeutics Options Trader Betting On A Major Dip For Stock By January 2024
Via Benzinga
FTC Seeks to Block Amgen's Acquisition of Horizon Therapeutics: What's Next for Both Stocks?
Via The Motley Fool
Is This Dow Jones Stock a Buy for Income Investors?
Via The Motley Fool
Why These 3 Nasdaq Stocks Buckled Today
Via The Motley Fool
FTC Files Lawsuit To Stop Amgen Buying Horizon Therapeutics, Sending Shockwaves Through Biopharma M&A
Via Benzinga
Dow Down More Than 200 Points On Blue Chip Earnings
Via Talk Markets
Why RH Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.